Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Operating Expenses (2016 - 2025)

Iovance Biotherapeutics has reported Operating Expenses over the past 13 years, most recently at $160.2 million for Q4 2025.

  • Quarterly results put Operating Expenses at $160.2 million for Q4 2025, changed 0.02% from a year ago — trailing twelve months through Dec 2025 was $666.9 million (up 19.22% YoY), and the annual figure for FY2025 was $666.9 million, up 19.22%.
  • Operating Expenses for Q4 2025 was $160.2 million at Iovance Biotherapeutics, down from $162.4 million in the prior quarter.
  • Over the last five years, Operating Expenses for IOVA hit a ceiling of $173.7 million in Q2 2025 and a floor of $110.3 million in Q2 2023.
  • Median Operating Expenses over the past 3 years was $140.3 million (2024), compared with a mean of $140.7 million.
  • Peak annual rise in Operating Expenses hit 44.0% in 2025, while the deepest fall reached 0.02% in 2025.
  • Iovance Biotherapeutics' Operating Expenses stood at $121.7 million in 2023, then surged by 31.65% to $160.3 million in 2024, then decreased by 0.02% to $160.2 million in 2025.
  • The last three reported values for Operating Expenses were $160.2 million (Q4 2025), $162.4 million (Q3 2025), and $173.7 million (Q2 2025) per Business Quant data.